Article
Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.
The Journal of infectious diseases - 1 May 1995
Staszewski S, Massari F E, Kober A, Göhler R, Durr S, Anderson K W, Schneider C L, Waterbury J A, Bakshi K K, Taylor V I
Abstract excerpt
L-697,661 is a human immunodeficiency virus type 1 (HIV-1)-specific nonnucleoside reverse transcriptase (RT) inhibitor. Its tolerability and activity in combination with zidovudine were evaluated in a 48-week double-blind study. One hundred nineteen zidovudine-naive HIV-1-infected patients with C...
Topics
- Adult
- Antiviral Agents
- Base Sequence
- Benzoxazoles
- CD4 Lymphocyte Count
- Double-Blind Method
- Drug Resistance, Microbial
- Drug Therapy, Combination
- Female
- HIV Infections
- HIV Reverse Transcriptase
- HIV-1
- Humans